Granada

• Efficacy and safety of 7 versus 14 days of antibiotic treatment for bacteremia produced by Pseudomonas aeruginosa: a multicenter, randomized … Recruiting
  2023-508441-41-00 6 2024-07-08 Bacteriemia producida por P. aeruginosa.
• A trial to learn how effective and safe odronextamab is compared to standard of care for adult participants with previously treated aggressi … Recruiting
  2022-502783-21-00 5 2024-02-20 B-Cell Non-Hodgkin's Lymphoma
• A trial to learn if odronextamab is safe and well-tolerated and how well it works compared to rituximab combined with different types of che … Recruiting
  2022-502660-20-00 5 2024-01-23 Follicular lymphoma
• A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the E … Recruiting
  2023-505121-14-00 5 2024-01-18 Moderate to Severe Plaque Psoriasis
• VB10.16 Plus Pembrolizumab in First Line r/m HNSCC Recruiting
  2022-503055-26-00 9 2023-10-30 Unresectable recurrent or metastatic HPV16 (Human Papilloma Virus) pos
• A Study of Zanubrutinib Versus Lenalidomide in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma (MAHOGANY) Recruiting
  2022-502548-12-00 5 2023-09-28 marginal zone lymphoma
• Combined Dose-Finding and CV Outcomes Study with CSL300 (Clazakizumab) in Adult Subjects with ESKD Undergoing Dialysis (POSIBIL6ESKD). Recruiting
  2022-500273-14-00 10 2023-07-17 Atherosclerotic cardiovascular disease in patients with ESKD
• Phase 3, Open-label Study of ARV-471 (PF-07850327) vs Fulvestrant in Participants With ER(+)/ HER2(-) Advanced Breast Cancer (VERITAC-2) Recruiting
  2022-500544-38-00 5 2023-06-05 Advanced Breast Cancer
• A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants with Early Breast Cancer (EMBER-4) Recruiting
  2022-501007-28-00 5 2023-04-18 Breast Neoplasms
• A Study to Compare the Efficacy and Safety of Oral Azacitidine (Oral-Aza, ONUREG®) plus BSC versus Placebo plus BSC in Participants with IPS … Recruiting
  2022-500479-29-00 10 2023-03-28 International Prognostic Scoring System-Revised (IPSS-R) Low - or Inte
• A randomized, open-label, phase II trial comparing neoadjuvant endocrine therapy in combination with trastuzumab, pertuzumab +/- the PI3K in … Recruiting
  2022-501152-28-00 4 2022-12-21 Breast Cancer
• Long-Term Safety and Efficacy evaluation of amlitelimab in participants of previous amlitelimab moderate to severe atopic dermatitis clinica … Recruiting
  2023-506548-18-00 10 2022-11-10 Dermatitis atopic
• CLINICAL TRIAL TO EVALUATE BLADDER INSTILLATION OF NEOADJUVANT CHEMOTHERAPY TO TRANSURETHRAL RESECTION OF THE BLADDER FOR THE PREVENTION OF … Recruiting
  2024-512683-53-00 6 2018-05-18 Non-muscle invasive bladder cancer
• HF-POLARIS: A research study to look at how well NNC0487-0111 works compared to placebo in people with heart failure and obesity Recruiting
  2025-523717-29-00 5 2026-04-28 HFpEF or HFmrEF and obesity
• A Study Evaluating BFB759 in Moderate to Severe Hidradenitis Suppurativa Recruiting
  2025-522440-41-00 4 2026-04-27 Hidradenitis Suppurativa
• A 16-Week Study to Learn About the Study Medicine Called Ritlecitinib in Adults With Long Lasting Painful Red Skin Lumps, Known by the Medic … Recruiting
  2025-522705-37-00 4 2026-04-21 HIDRADENITIS SUPPURATIVA
• Study of ART6043 in Advanced/​Metastatic Solid Tumors Patients Recruiting
  2023-509220-17-00 7 2026-04-10 Metastatic solid tumors
• Phase 3 Efficacy and Safety of Lebrikizumab in Adults With Nummular Eczema (LUMINE) Recruiting
  2025-522403-17-00 5 2026-04-10 Nummular Dermatitis
• A clinical trial to learn about the effects of AMO959 given with AAA617 and an androgen receptor pathway inhibitor (ARPI) in adults with PSM … Recruiting
  2025-521859-23-00 9 2026-03-31 PSMA-positive mCRPC with prior exposure to at least one prior ARPI
• A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab ( Switch-Up ) Recruiting
  2025-523347-35-00 11 2026-03-05 Atopic Dermatitis
• Effect of intravenous iron on quality of life in older adults with acute coronary syndrome: a phase IV clinical study Recruiting
  2025-522421-36-00 6 2026-02-27 Acute coronary syndrome
• Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer (OPERA-02) Recruiting
  2025-522873-12-00 5 2026-02-24 ER+, HER2- Advanced Breast Cancer
• Patient-Centered Study of T-DXd in Metastatic HER2-Positive Breast Cancer with Real-Life Side Effect Management Recruiting
  2025-521805-41-00 5 2026-02-18 Patients with HER2-positive, locally advanced or metastatic breast can
• A Study of Dato-DXd in Inoperable or Metastatic Hormone Receptor-positive, HER2 IHC 0 Breast Cancer Recruiting
  2025-521904-23-00 4 2026-02-17 Locally Advanced Inoperable or Metastatic Breast Cancer Refractory to

Showing 73–96 of 382 trials